These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 15115191)

  • 1. Phosphodiesterase type 5 inhibitor differentiation based on selectivity, pharmacokinetic, and efficacy profiles.
    Seftel AD
    Clin Cardiol; 2004 Apr; 27(4 Suppl 1):I14-19. PubMed ID: 15115191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil.
    Saenz de Tejada I; Angulo J; Cuevas P; Fernández A; Moncada I; Allona A; Lledó E; Körschen HG; Niewöhner U; Haning H; Pages E; Bischoff E
    Int J Impot Res; 2001 Oct; 13(5):282-90. PubMed ID: 11890515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficacy and safety of PDE5 inhibitors.
    Rashid A
    Clin Cornerstone; 2005; 7(1):47-56. PubMed ID: 16156423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphodiesterase type 5 as a pharmacologic target in erectile dysfunction.
    Corbin JD; Francis SH; Webb DJ
    Urology; 2002 Sep; 60(2 Suppl 2):4-11. PubMed ID: 12414329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Binding of tritiated sildenafil, tadalafil, or vardenafil to the phosphodiesterase-5 catalytic site displays potency, specificity, heterogeneity, and cGMP stimulation.
    Blount MA; Beasley A; Zoraghi R; Sekhar KR; Bessay EP; Francis SH; Corbin JD
    Mol Pharmacol; 2004 Jul; 66(1):144-52. PubMed ID: 15213306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential effects of the phosphodiesterase type 5 inhibitors sildenafil, vardenafil, and tadalafil in rat aorta.
    Teixeira CE; Priviero FB; Webb RC
    J Pharmacol Exp Ther; 2006 Feb; 316(2):654-61. PubMed ID: 16204472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of cyclic GMP-binding cyclic GMP-specific phosphodiesterase (Type 5) by sildenafil and related compounds.
    Turko IV; Ballard SA; Francis SH; Corbin JD
    Mol Pharmacol; 1999 Jul; 56(1):124-30. PubMed ID: 10385692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro.
    Wallis RM; Corbin JD; Francis SH; Ellis P
    Am J Cardiol; 1999 Mar; 83(5A):3C-12C. PubMed ID: 10078537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacology and drug interaction effects of the phosphodiesterase 5 inhibitors: focus on alpha-blocker interactions.
    Kloner RA
    Am J Cardiol; 2005 Dec; 96(12B):42M-46M. PubMed ID: 16387566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nebivolol potentiates the efficacy of PDE5 inhibitors to relax corpus cavernosum and penile arteries from diabetic patients by enhancing the NO/cGMP pathway.
    Martínez-Salamanca JI; La Fuente JM; Cardoso J; Fernández A; Cuevas P; Wright HM; Angulo J
    J Sex Med; 2014 May; 11(5):1182-92. PubMed ID: 24877179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phosphodiesterase 5 inhibitors--drug design and differentiation based on selectivity, pharmacokinetic and efficacy profiles.
    Supuran CT; Mastrolorenzo A; Barbaro G; Scozzafava A
    Curr Pharm Des; 2006; 12(27):3459-65. PubMed ID: 17017939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overview of phosphodiesterase 5 inhibition in erectile dysfunction.
    Rosen RC; Kostis JB
    Am J Cardiol; 2003 Nov; 92(9A):9M-18M. PubMed ID: 14609619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vardenafil: a novel type 5 phosphodiesterase inhibitor for the treatment of erectile dysfunction.
    Kendirci M; Bivalacqua TJ; Hellstrom WJ
    Expert Opin Pharmacother; 2004 Apr; 5(4):923-32. PubMed ID: 15102574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms of action of PDE5 inhibition in erectile dysfunction.
    Corbin JD
    Int J Impot Res; 2004 Jun; 16 Suppl 1():S4-7. PubMed ID: 15224127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phosphodiesterase type 5 inhibitors: molecular pharmacology and interactions with other phosphodiesterases.
    Seftel AD
    Curr Pharm Des; 2005; 11(31):4047-58. PubMed ID: 16378510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes.
    Ballard SA; Gingell CJ; Tang K; Turner LA; Price ME; Naylor AM
    J Urol; 1998 Jun; 159(6):2164-71. PubMed ID: 9598563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phosphodiesterase 5 inhibitors for erectile dysfunction.
    Setter SM; Iltz JL; Fincham JE; Campbell RK; Baker DE
    Ann Pharmacother; 2005; 39(7-8):1286-95. PubMed ID: 15941818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vardenafil: a review of its use in erectile dysfunction.
    Keating GM; Scott LJ
    Drugs; 2003; 63(23):2673-703. PubMed ID: 14636086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphodiesterase-5 Gln817 is critical for cGMP, vardenafil, or sildenafil affinity: its orientation impacts cGMP but not cAMP affinity.
    Zoraghi R; Corbin JD; Francis SH
    J Biol Chem; 2006 Mar; 281(9):5553-8. PubMed ID: 16407275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PDE5 inhibitors: are there differences?
    Carson CC
    Can J Urol; 2006 Feb; 13 Suppl 1():34-9. PubMed ID: 16526979
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.